SCHEMBL5360241

SCHEMBL5360241

OC(CNCc1cccs1)COc1cccc(-c2noc3cc(F)ccc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.37
RAB9A P51151 1/20 0.37
TSHR P16473 5/20 0.36
ADRB1 P08588 2/20 0.35
ADRB3 P13945 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ADRB2 P07550 1/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
ALDH1A1 P00352 4/20 0.34
CYP1A2 P05177 4/20 0.34
CYP3A4 P08684 4/20 0.34
CYP2D6 P10635 4/20 0.34
CYP2C19 P33261 4/20 0.34
MAPK1 P28482 3/20 0.34
CLK4 Q9HAZ1 3/20 0.34
HPGD P15428 2/20 0.34
TP53 P04637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364413 1.00 NPC1 (0.37) NPC1RAB9ATSHRADRB1ADRB3
SCHEMBL1384655 1.00 NPC1 (0.37) NPC1RAB9ATSHRADRB1ADRB3
SCHEMBL1381536 0.91 NPC1 (0.41) NPC1TSHRADRB1ADRB3HTR1A
SCHEMBL5371343 0.91 NPC1 (0.41) NPC1TSHRADRB1ADRB3HTR1A
SCHEMBL1381528 0.91 NPC1 (0.41) NPC1TSHRADRB1ADRB3HTR1A
SCHEMBL5359732 0.88 NPC1 (0.49) NPC1ADRB1ADRB3ADRB2HTR2A
SCHEMBL5359736 0.88 NPC1 (0.49) NPC1ADRB1ADRB3ADRB2HTR2A
SCHEMBL5359727 0.88 NPC1 (0.49) NPC1ADRB1ADRB3ADRB2HTR2A
SCHEMBL1382995 0.87 NPC1 (0.41) NPC1ADRB1ADRB3ADRB2HTR1A
SCHEMBL5359446 0.87 MEN1 (0.45) NPC1ADRB1ADRB3ADRB2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253165-B2 Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists AVENTIS PHARMACEUTICALS INC. (US) 2007-08-07 US claimed
US-20050107377-A1 Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists AVENTIS PHARMACEUTIALS INC. (US) 2005-05-19 US claimed
EP-1216244-B1 Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists AVENTIS PHARMA INC (US) 2003-08-13 EP claimed
US-7253165-B2 Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists AVENTIS PHARMACEUTICALS INC. (US) 2007-08-07 US disclosed
US-20050107377-A1 Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists AVENTIS PHARMACEUTIALS INC. (US) 2005-05-19 US disclosed
EP-1216244-B1 Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists AVENTIS PHARMA INC (US) 2003-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107377-A1 Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists DRD4, DRD2, DRD1 NPC1 2469/4885RAB9A 2015/4885TSHR 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.